609 related articles for article (PubMed ID: 28556678)
1. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
2. Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.
Jamy O; Sonpavde G
Expert Opin Emerg Drugs; 2017 Dec; 22(4):347-355. PubMed ID: 29226734
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatments for metastatic urothelial carcinoma.
Lalani AA; Sonpavde GP
Expert Opin Pharmacother; 2019 Feb; 20(2):201-208. PubMed ID: 30412003
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
6. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
8. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
9. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
[TBL] [Abstract][Full Text] [Related]
13. Novel molecular targets for the therapy of urothelial carcinoma.
Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
[TBL] [Abstract][Full Text] [Related]
14. Options in metastatic urothelial cancer after first-line therapy.
Alimohamed NS; Sridhar SS
Curr Opin Support Palliat Care; 2015 Sep; 9(3):255-60. PubMed ID: 26262830
[TBL] [Abstract][Full Text] [Related]
15. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
16. Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
Morales-Barrera R; Suárez C; de Castro AM; Racca F; Valverde C; Maldonado X; Bastaros JM; Morote J; Carles J
Cancer Treat Rev; 2016 Nov; 50():208-216. PubMed ID: 27743530
[TBL] [Abstract][Full Text] [Related]
17. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
[TBL] [Abstract][Full Text] [Related]
18. The landscape of immunotherapy in metastatic urothelial carcinoma.
Teo MY; Iyer G
Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
[TBL] [Abstract][Full Text] [Related]
19. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
